The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke
Qiang Donga, Yi Donga, Liping Liub, Anding Xuc, Yusheng Zhangc, Huaguang Zhengb, Yongjun Wangb✉
- aDepartment of Neurology, Huashan Hospital affiliated to Fudan University, Shanghai Shi, China
- bDepartment of Neurology, Beijing Tiantan Hospital affiliated to Capital Medical University, Beijing, China
- cDepartment of Neurology and Stroke Center, First Affiliated Hospital, Jinan University, Guangzhou Shi, China
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
The most effective medical treatment for acute ischaemic stroke (AIS) is to offer intravenous thrombolysis during the ultra-early period of time after the onset. Even based on the Consensus of Chinese Experts on Intravenous Thrombolysis for AIS in 2012 and 2014 Chinese Guidelines on the Diagnosis and Treatment of AIS, the rate of thrombolysis for AIS in China remained around 2.4%, and the rate of intravenous tissue plasminogen activator usage was only about 1.6% in real world. The indication of thrombolysis for AIS has been expanded, and contraindications have been reduced with recently published studies. In order to facilitate the standardisation of treating AIS, improve the rate of thrombolysis and benefit patients who had a stroke, Chinese Stroke Association has organised and developed this scientific statement.
TL;DRIn order to facilitate the standardisation of treating AIS, improve the rate of thrombolysis and benefit patients who had a stroke, Chinese Stroke Association has organised and developed this scientific statement. (Semantic Scholar)